117 related articles for article (PubMed ID: 15332559)
1. The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy.
Akaza H; Naito S; Chang SJ; Chen KK; Cheng C; Choi HY; Fujioka T; Hinotsu S; Hirao Y; Hong SJ; Kim CS; Kim WJ; Lee SE; Murai M; Ogawa O; Rim JS; Soebadi DM; Song JM; Tsukamoto T; Umbas R; Usami M; Xia S; Yang CR; Yoon JH; Zhou L
Gan To Kagaku Ryoho; 2004 Aug; 31(8):1285-95. PubMed ID: 15332559
[TBL] [Abstract][Full Text] [Related]
2. The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy.
Akaza H; Moore MA; Chang SJ; Cheng C; Choi HY; Esuvaranathan K; Hinotsu S; Hong SJ; Kim CS; Kim WJ; Murai M; Naito S; Soebadi D; Song JM; Umbas R; Usami M; Xia S; Yang CR
Asian Pac J Cancer Prev; 2007; 8(1):3-12. PubMed ID: 17477764
[TBL] [Abstract][Full Text] [Related]
3. [Hormonal treatment of cancer of the prostate: review and present status].
Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
[No Abstract] [Full Text] [Related]
4. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
5. [Total androgen blockade].
Namiki M; Mizokami A
Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
[No Abstract] [Full Text] [Related]
6. [Endocrine therapy for prostate cancer in the future].
Usami M
Gan To Kagaku Ryoho; 1998 May; 25(6):817-22. PubMed ID: 9617319
[TBL] [Abstract][Full Text] [Related]
7. Asian trends in prostate cancer hormone therapy.
Akaza H; Naito S; Cheng C; Kaisary A; Soebadi DM; Umbas R; Esuvaranathan K; Gu FL; Zhou L; Hong SJ; Kim WJ; Lee SE; Rim JS; Song JM; Yoon JH; Chang SJ; Huang CH; Yang CR; Hirao Y; Murai M; Tsukamoto T; Usami M
Gan To Kagaku Ryoho; 2002 Nov; 29(11):1951-61. PubMed ID: 12465395
[TBL] [Abstract][Full Text] [Related]
8. The 2nd conference on Asian trends in prostate cancer hormone therapy.
Akaza H; Chang SJ; Chen KK; Esuvaranathan K; Fujioka T; Hirao Y; Hong SJ; Hinotsu S; Kim WJ; Lau W; Lee SE; Murai M; Naito S; Ogawa O; Rim JS; Soebadi DM; Song JM; Tsukamoto T; Umbas R; Usami M; Yang CR; Yoon JH; Zhou L
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1533-42. PubMed ID: 14584292
[TBL] [Abstract][Full Text] [Related]
9. [Usefulness and positioning of MAB therapy for prostate cancer].
Akaza H; Chodak GW; Hirao Y
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
[TBL] [Abstract][Full Text] [Related]
10. Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
Washino S; Hirai M; Saito K; Kobayashi Y; Arai Y; Miyagawa T
Low Urin Tract Symptoms; 2018 Jan; 10(1):57-63. PubMed ID: 27943566
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Lodde M; Lacombe L; Fradet Y
Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
[TBL] [Abstract][Full Text] [Related]
12. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
Moul JW
Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
[No Abstract] [Full Text] [Related]
13. [Reevaluation of MAB therapy and progress of endocrine therapy].
Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
[No Abstract] [Full Text] [Related]
14. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
[TBL] [Abstract][Full Text] [Related]
15. [First line therapy in the treatment of metastatic prostate cancer].
Sakai H; Kanetake H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program.
Wirth MP; Froehner M
Oncology; 2003; 65 Suppl 1():1-4. PubMed ID: 12949426
[TBL] [Abstract][Full Text] [Related]
17. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes.
Akaza H; Hinotsu S; Cooperberg MR; Chung BH; Youl Lee J; Umbas R; Tsukamoto T; Namiki M; Carroll P
Jpn J Clin Oncol; 2013 Jul; 43(7):756-66. PubMed ID: 23723314
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
[TBL] [Abstract][Full Text] [Related]
19. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
[TBL] [Abstract][Full Text] [Related]
20. [Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate].
Boccon-Gibod L
Prog Urol; 1997 Feb; 7(1):97-8. PubMed ID: 9116748
[No Abstract] [Full Text] [Related]
[Next] [New Search]